



Caladrius Biosciences to Participate at the Upcoming September Conferences

September 5, 2019

BASKING RIDGE, N.J. (September 5, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today that management will participate in the following conferences in September:

21st Annual Global Investment Conference, Sponsored by H.C. Wainwright

Date & Time: Tuesday, September 10, 2019 at 12:05 p.m. (EDT)

Presenter: David J. Mazzo, Ph.D.

Venue: Lotte New York Palace Hotel in New York, NY

Live Webcast: wsw.com/webcast/hcw5/clbs/

Texas Heart Institute: Cardiology Grand Rounds

Title: The Microcirculation: Center of the Cardiovascular Regenerative Medicine Universe

Date & Time: Friday, September 13, 2019 at 12:00 p.m. (CDT)

Presenter: Douglas W. Losordo, MD, FACC, FAHA Executive Vice President, Global Head of Research and Development, Chief Medical Officer

Venue: Texas Heart Institute Denton A. Cooley Auditorium

Live Webcast: Texasheart.org/grandrounds

Investing for Cures 2019

Date & Time: Thursday, September 19, 2019 at 9:55 a.m. (EDT)

Presenter: David J. Mazzo, Ph.D.

Venue: Club 101, 101 Park Avenue in New York, NY

Cincinnati College of Pharmacy Seminar Series

Title: The CD34 Cell: Experimental Evidence in Animals and Humans for Angiogenesis and Ischemic Repair

Date & Time: Thursday, September 19, 2019 at 5:00 p.m. (EST)

Presenter: William K. Sietsema, Ph.D., Vice President, Global Regulatory Affairs

Venue: University of Cincinnati College of Pharmacy

About Caladrius Biosciences

Caladrius is a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies for select cardiovascular and autoimmune diseases. Our leadership team collectively has decades of biopharmaceutical development experience and world-recognized scientific achievement in the fields of cardiovascular and autoimmune disease, among other areas. Our current product candidates include three developmental treatments for cardiovascular diseases based on our CD34+ cell therapy platform: CLBS12, recipient of a SAKIGAKE designation in Japan and advanced therapy medicinal product classification (ATMP) in Europe, eligible for early conditional approval for the treatment of critical limb ischemia in Japan based on an ongoing clinical trial; CLBS16, subject of the proof-of-concept ESCaPE-CMD clinical trial in the U.S.A. for the treatment of coronary microvascular dysfunction; and CLBS14, recipient of a RMAT designation in the U.S.A. and for which we are in preparation to commence a Phase 3 clinical trial in no option refractory disabling angina. For more information on the company, please visit www.caladrius.com.

Contact:

Investors:

Caladrius Biosciences, Inc.

John Menditto

Vice President, Investor Relations and Corporate Communications

Phone: +1-908-842-0084

Email: jmenditto@caladrius.com



Source: Caladrius Biosciences, Inc.